BiomX Inc. Earnings Recaps
Q3 2025
Nov 12, 2025
BiomX reported significant advancements in its clinical programs despite regulatory challenges, maintaining confidence in its innovative phage therapy pipeline.
Key takeaways
- Initiated Phase IIb trial for BX004 with first patient dosing, though faced a temporary clinical hold from the FDA related to the nebulizer delivery device.
- Received positive FDA feedback on BX011’s development for diabetic foot infections, outlining a clear pathway towards a Biologics License Application (BLA).
- European trials for BX004 continue without interruption, with planned data reporting set for Q1 2026.
- BX011 targets a critical unmet need in diabetic foot infections, promising substantial commercial potential in a market with no new drugs approved in over 20 years.
- Company remains optimistic about upcoming discussions with the FDA and the Department of Defense Health Agency as part of its strategic partnerships.
Q2 2025
Aug 13, 2025
BiomX delivered noteworthy advancements in its clinical pipeline during Q2 2025, highlighted by the successful initiation of its Phase IIb trial for BX004 and positive data for BX211, positioning the company well for future growth.
Key takeaways
- Initiated patient dosing in Phase IIb trial for BX004, targeting cystic fibrosis, with top-line results expected in Q1 2026.
- Published significant Phase Ib/IIa results for BX004, demonstrating a 500-fold improvement in bacterial reduction without resistance emergence.
- BX211 received strong endorsements from key opinion leaders following positive Phase II results, emphasizing its potential in treating diabetic foot osteomyelitis.
- Continued discussions are underway with the U.S. Defense Health Agency regarding BX211's registrational study and FDA feedback expected in H2 2025.